Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytosorbents Corp CTSO

Healthcare Medical Devices
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive... see more

Recent & Breaking News (NDAQ:CTSO)

CytoSorbents Reports First Quarter 2023 Results

GlobeNewswire May 2, 2023

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

GlobeNewswire April 26, 2023

CytoSorbents' Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled

GlobeNewswire April 20, 2023

CytoSorbents Announces Board Chairman Al W. Kraus To Retire

GlobeNewswire April 19, 2023

Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation

GlobeNewswire March 29, 2023

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

GlobeNewswire March 22, 2023

CytoSorbents Comments on Bank Exposure and Diversified Cash Position

GlobeNewswire March 14, 2023

CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

GlobeNewswire March 9, 2023

New European "Guidelines for the Management of Severe Perioperative Bleeding" Consider Hemoadsorption for the First-Time

GlobeNewswire March 7, 2023

CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference

PR Newswire February 27, 2023

CytoSorbents to Report Fiscal 2022 Operating and Financial Results

PR Newswire February 24, 2023

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

PR Newswire January 31, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

PR Newswire January 23, 2023

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

PR Newswire January 17, 2023

CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement

PR Newswire December 29, 2022

CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications

PR Newswire December 21, 2022

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled

PR Newswire November 14, 2022

CytoSorbents Reports Third Quarter 2022 Financial and Operational Results

PR Newswire November 3, 2022

'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals

PR Newswire November 2, 2022

National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma

PR Newswire October 31, 2022